Compound ID | 1786
ALS-4
Class: Antivirulence agent
| Spectrum of activity: | Gram-positive |
| Details of activity: | Inhibits the biosynthesis of staphyloxanthin, which contributes to the resistance to reactive oxygen species (ROS) and host neutrophil-based killing |
| Combined with other compounds: | Yes |
| Description: | Orally administered small molecule drug; little impact on ex vivo survival of the bacterium |
| Institute where first reported: | Aptorum Group |
| Year first mentioned: | 2017 |
| Highest developmental phase: | Phase 1 |
| Development status: | Active (as of 2022) |
| External links: | |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.